BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...

The Global Innovation Index 2025 report revealed that China leads globally in its number of innovation clusters, boasting 24 ...